LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

179.7 2.4

Visão Geral

Variação de preço das ações

24h

Atual

Mín

175.39

Máximo

180.87

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

EPS

2.43

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+16.28% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

852M

8.8B

Abertura anterior

177.3

Fecho anterior

179.7

Sentimento de Notícias

By Acuity

74%

26%

322 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de mar. de 2026, 23:39 UTC

Ações em Alta

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 de mar. de 2026, 23:20 UTC

Ganhos

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 de mar. de 2026, 21:43 UTC

Ganhos

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 de mar. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

4 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 de mar. de 2026, 23:24 UTC

Conversa de Mercado

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 de mar. de 2026, 22:30 UTC

Ganhos

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 de mar. de 2026, 22:30 UTC

Ganhos

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 de mar. de 2026, 22:30 UTC

Ganhos

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 de mar. de 2026, 22:13 UTC

Ganhos

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 de mar. de 2026, 22:13 UTC

Ganhos

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 de mar. de 2026, 22:13 UTC

Ganhos

Vermilion Energy 4Q EPS C$2.86 >VET

4 de mar. de 2026, 22:04 UTC

Conversa de Mercado

RBA Slipping Behind The Curve On Rates -- Market Talk

4 de mar. de 2026, 21:53 UTC

Ganhos

Lithium Americas 4Q Rev $66.8M >LAC

4 de mar. de 2026, 21:53 UTC

Ganhos

Lithium Americas 4Q Loss/Shr 52c >LAC

4 de mar. de 2026, 21:52 UTC

Ganhos

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 de mar. de 2026, 21:50 UTC

Ganhos

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 de mar. de 2026, 21:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de mar. de 2026, 21:48 UTC

Ganhos

Webull 4Q Rev $165.2M >BULL

4 de mar. de 2026, 21:48 UTC

Ganhos

Webull 4Q EPS 1c >BULL

4 de mar. de 2026, 21:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de mar. de 2026, 21:45 UTC

Conversa de Mercado

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 de mar. de 2026, 21:40 UTC

Ganhos

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 de mar. de 2026, 21:36 UTC

Notícias Principais

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 de mar. de 2026, 21:27 UTC

Ganhos

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 de mar. de 2026, 21:17 UTC

Conversa de Mercado

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 de mar. de 2026, 21:16 UTC

Ganhos

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 de mar. de 2026, 21:15 UTC

Ganhos

Broadcom 1Q EPS $1.50 >AVGO

4 de mar. de 2026, 21:15 UTC

Ganhos

Broadcom 1Q Net $7.35B >AVGO

4 de mar. de 2026, 21:15 UTC

Ganhos

Broadcom 1Q Rev $19.31B >AVGO

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

16.28% parte superior

Previsão para 12 meses

Média 204.3 USD  16.28%

Máximo 265 USD

Mínimo 175 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

8

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

322 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat